Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas

Human Pathology

Volumn 30, Issue 3, 1999, Pages 339-344

  Massi, Daniela ^b   Franchi, Alessandro ^b   Borgognoni, Lorenzo ^b   Reali, Umberto Maria ^b   Santucci, Marco ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b NONE

Author keywords

Acidic and Rich in Cysteine; Cutaneous melanomas; Immunohistochemistry; Osteonectin Secreted Protein; Prognostic factors

Indexed keywords

OSTEONECTIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MELANOMA; OUTCOMES RESEARCH; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE;

EID: 0032982090     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(99)90014-X     Document Type: Article

References (43)

1. Breslow A, Macht SD: Evaluation of prognosis in stage I cutaneous melanoma. Plast Reconstr Surg 61:342-346, 1978
2. Bagley FH, Cady B, Lee A, et al: Changes in clinical presentation and management of malignant melanoma. Cancer 47:2126-2134, 1981
3. Rigel DS, Friedman RJ, Kopf AW, et al: Factors influencing survival in melanoma. Dermatol Clin 9:631-642, 1991
4. Naruns PL, Nizze JA, Cochran AJ, et al: Recurrence potential of thin primary melanomas. Cancer 57:545-548, 1986
5. Shaw HM, McCarthy WH, McCarthy SW, et al: Thin malignant melanomas and recurrence potential. Arch Surg 112:1147-1150, 1987
6. Slingluff CL, Vollmer RT, Reintgen DS, et al: Lethal "thin" malignant melanoma: Identifying patients at risk. Am Surg 208:150-161, 1988
7. Glass LF, Guffey JM, Schroer KR, et al: Histopathological study of recurrent Clark level II melanomas. Semin Surg Oncol 9:202-207, 1993
8. Vilmer C, Bailly C, Le Doussal V, et al: Thin melanomas with unusual aggressive behavior: A report of nine cases. J Am Acad Dermatol 34:439-444, 1996
9. Balch CM, Soon SJ, Shaw HM, et al: An analysis of prognostic factors in 4000 patients with cutaneous melanoma, in Balch CM, Milton GW (eds): Cutaneous melanoma: Clinical management and treatment results worldwide (ed 1). Philadelphia, J.B. Lippincott, 1985, pp 321-352
10. Clark WH Jr, Elder DE, DuPont GIV, et al: Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81:1893-1904, 1989
11. Gromet M, Epstein W, Blois MS: The regressing thin malignant melanoma: A distinctive lesion with metastatic potential. Cancer 42:2282-2292, 1978
12. Paladugu RR, Yonemoto RH: Biologic behavior of thin malignant melanomas with regressive changes. Arch Surg 118:41-44, 1983
13. Barnhill RL, Levy MA: Regressing thin cutaneous malignant melanomas (≤ 1.0 mm) are associated with angiogenesis. Am J Pathol 143:99-104, 1993
14. Graham CH, Rivers J, Kerbel RS, et al: Extent of vascularization as a prognostic indicator in thin (<0.76 mm) malignant melanomas. Am J Pathol 145:510-514, 1994
15. Shaw HM, McCarthy SW, McCarthy WH, et al: Thin regressing malignant melanoma: Significance of concurrent regional lymph node metastases. Histopathology 15:257-265, 1989
16. Busam KJ, Berwick M, Blessing K, et al: Tumor vascularity is not a prognostic factor for malignant melanoma of the skin. Am J Pathol 147:1049-1056, 1995
17. Sage EH, Vernon R, Decker J, et al: Distribution of the calcium-binding protein SPARC in tissues of embryonic and adult mice. J Histochem Cytochem 37:819-829, 1989
18. Sage EH, Bornstein P: Extracellular proteins that modulate cell-matrix interactions. SPARC, tenascin, and thrombospondin. J Biol Chem 266:14831-14834, 1991
19. Tremble PM, Lane TF, Sage EH, et al: SPARC, a secreted protein associate with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway. J Cell Biol 121:1433-1444, 1993
20. Lane TF, Iruela-Arispe ML, Johnson RS, et al: SPARC is a source of copper-binding peptides that stimulate angiogenesis. J Cell Biol 125:929-943, 1994
21. Sage EH: Terms of attachment: SPARC and tumorigenesis. Nature Med 3:144-146, 1997
22. Lane TF, Iruela-Arispe ML, Sage EH: Regulation of gene expression by SPARC during angiogenesis in vitro. Changes in fibronectin, thrombospondin-1 and plasminogen activator inhibitor-1. J Biol Chem 267:16736-16745, 1992
23. Funk SE, Sage EH: Differential effects of SPARC and cationic SPARC peptides on DNA synthesis by endothelial cells and fibroblasts. J Cell Physiol 154:53-63, 1993
24. Kamihagi K, Katayama M, Ouchi R, et al: Osteonectin/ SPARC regulates cellular secretion rates of fibronectin and laminin extracellular matrix proteins. Biochem Bioph Res Comm 15:423-428, 1994
25. Goldblum SE, Ding X, Funk SE, et al: SPARC (secreted protein acidic and rich in cysteine) regulates endothelial cell shape and barrier function. Proc Natl Acad Sci USA 91:3448-3452, 1994
26. Porte H, Chastre E, Prevot S, et al: Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int J Cancer 64:70-75, 1995
27. Porter PL, Sage EH, Lane TF, et al: Distribution of SPARC in normal and neoplastic human tissue. J Histochem Cytochem 43:791-800, 1995
28. Bellahcene A, Castronovo V: Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol 146:95-100, 1995
29. Podhajcer OL, Wolf C, Lefebvre O, et al: Comparative expression of the SPARC and stromelysin-3 genes in mammary tumors. Breast 5:13-20, 1996
30. Ledda MF, Adris S, Bravo AI, et al: Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nature Med 3:171-176, 1997
31. Ledda F, Bravo AI, Adris S, et al: The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol 108:210-214, 1997
32. Clark WH, Fromm L, Bernardino EA, et al: The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 29:705-726, 1969
33. Breslow A: Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 172:902-908, 1970
34. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
35. Hasselaar P, Loskutoff DJ, Sawdey M, et al: SPARC induces the expression of type 1 plasminogen activator inhibitor in cultured bovine aortic endothelial cells. J Biol Chem 266:13178-13184, 1991
36. + binding glycoprotein SPARC modulated cell cycle progression in bovine aortic endothelial cells. Proc Natl Acad Sci USA 88:2648-2652, 1991
37. Mansson-Brahme E, Carstensen J, Erhardt K, et al: Prognostic factors in thin cutaneous malignant melanoma. Cancer 73:2324-2332, 1994
38. Barnhill RL, Fine JA, Roush GC, et al: Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 78:427-432, 1996
39. Kopf AW, Welkovich B, Frakel RE, et al: Thickness of malignant melanoma: Global analysis of related factors: J Dermatol Surg Oncol 13:345-420, 1987
40. Cook MG: The significance of inflammation and regression in melanoma (editorial). Virchows Archiv A (Pathol Anat) 420:113-115, 1992
41. Massi D, Franchi A, Borgognoni L, et al: Thin cutaneous malignant melanomas (≤1.5 mm). Cancer (in press) 1999
42. Baset P, Bellocq JP, Wolf C, et al: A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature (Lond.) 348:699-704, 1990
43. Wrana JL, Overall CM, Sodek J: Regulation of the expression of a secreted acidic protein rich in cysteine (SPARC) in human fibroblasts by transforming growth factor β. Comparison of transcriptional and post-transcriptional control with fibronectin and type I collagen. Europ J Biochem 197:519-528, 1991